12 Month Price Forecast For INDV
Distance to INDV Price Forecasts
INDV Price Momentum
๐ค Considering Indivior (INDV)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 1:57 AM UTC
INDV Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, INDV has a consensus that is bullish. The median price target is $16.00, with forecasts ranging from $16.00 to $16.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With INDV currently trading at $11.40, the median price forecast suggests a 40.4% upside. The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 40.4% upside, while David Amsellem at Piper Sandler provides the most conservative target, suggesting a 40.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INDV Analyst Consensus
INDV Price Target Range
Latest INDV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INDV.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Oct 25, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $16.00 |
Oct 11, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $16.00 |
Oct 11, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $15.00 |
Sep 13, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $22.00 |
Jul 23, 2024 | Piper Sandler | David Amsellem | Overweight | Initiates | $22.00 |
Jul 10, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $24.00 |
Apr 3, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $37.00 |
Stocks Similar to Indivior PLC - Ordinary Shares
The following stocks are similar to Indivior based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Indivior PLC - Ordinary Shares (INDV) Financial Data
Indivior PLC - Ordinary Shares has a market capitalization of $1.41B with a P/E ratio of 272.0x. The company generates $1.18B in trailing twelve-month revenue with a -0.3% profit margin.
Revenue growth is +13.3% quarter-over-quarter, while maintaining an operating margin of +30.6% and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Indivior PLC - Ordinary Shares (INDV) Company Overview
About Indivior PLC - Ordinary Shares
Develops drugs for opioid dependence treatment.
The company generates revenue by developing, manufacturing, and selling prescription medications primarily focused on treating opioid dependence and related disorders. Its core products, including SUBLOCADE and SUBOXONE, are marketed in the United States and internationally, contributing to its earnings through direct sales and partnerships for ongoing drug development.
Indivior PLC is actively engaged in research and development of new treatments, including several drugs currently in various clinical trial phases. The company collaborates with other organizations for the advancement of its products, indicating a strong commitment to innovation in the treatment of substance use disorders. Established in 2014 and based in Virginia, Indivior is positioned in a critical healthcare sector addressing significant public health challenges.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,000
CEO
Mr. Mark Crossley
Country
United States
IPO Year
2014
Website
www.indivior.comIndivior PLC - Ordinary Shares (INDV) Latest News & Analysis
A study indicates that once-monthly SUBLOCADE enhances retention in opioid use disorder patients, particularly those with fentanyl. A second injection was given a week later for quicker medication levels.
Improved retention rates and faster medication levels for OUD patients with SUBLOCADE could enhance market share and revenue for the product, signaling potential growth for the pharmaceutical company involved.
Indivior PLC is considering proposals from Oaktree Capital Management for enhancing shareholder value while maintaining its current strategy. The company emphasizes engagement with the investor.
Indivior's openness to Oaktree's proposals signals potential changes in governance and strategy, which could impact shareholder value and stock performance.
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
2 months agoIndivior PLC's Board acknowledged receipt of a letter from Oaktree Capital Management on November 7, 2024.
Oaktree's letter to Indivior's Board may signal potential strategic changes or influence, impacting stock performance and investor sentiment.
Indivior PLC highlighted the effectiveness and safety of SUBLOCADEยฎ for opioid use disorder treatment, emphasizing its role in improving outcomes like abstinence and recovery during Substance Abuse Prevention Month.
Positive data on SUBLOCADE's effectiveness in treating opioid use disorder can boost Indivior's market position and investor confidence, potentially leading to increased sales and stock performance.
Indivior moves to shore up confidence in Sublocade
3 months agoIndivior PLC maintains its full-year outlook despite a recent profit warning. The company faces short-term challenges but aims to reassure investors amid rising competition.
Indivior's steady outlook amidst recent profit warnings signals mixed confidence, impacting market perceptions of its resilience against competition and future performance.
Indivior PLC's share price rose 11% after reaffirming its full-year outlook. Q3 revenue increased 13% to $307M, with Sublocade sales up 14% to $191M.
Indivior's 11% share price jump signals investor confidence after strong Q3 results and reaffirmed guidance, despite competitive pressures on Sublocade, indicating potential growth resilience.
Frequently Asked Questions About INDV Stock
What is Indivior PLC - Ordinary Shares's (INDV) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Indivior PLC - Ordinary Shares (INDV) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $16.00.
Is INDV stock a good investment in 2025?
According to current analyst ratings, INDV has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for INDV stock?
Wall Street analysts predict INDV stock could reach $16.00 in the next 12 months. This represents a 40.4% increase from the current price of $11.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Indivior PLC - Ordinary Shares's business model?
The company generates revenue by developing, manufacturing, and selling prescription medications primarily focused on treating opioid dependence and related disorders. Its core products, including SUBLOCADE and SUBOXONE, are marketed in the United States and internationally, contributing to its earnings through direct sales and partnerships for ongoing drug development.
What is the highest forecasted price for INDV Indivior PLC - Ordinary Shares?
The highest price target for INDV is $16.00 from David Amsellem at Piper Sandler, which represents a 40.4% increase from the current price of $11.40.
What is the lowest forecasted price for INDV Indivior PLC - Ordinary Shares?
The lowest price target for INDV is $16.00 from David Amsellem at Piper Sandler, which represents a 40.4% increase from the current price of $11.40.
What is the overall INDV consensus from analysts for Indivior PLC - Ordinary Shares?
The overall analyst consensus for INDV is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are INDV stock price projections?
Stock price projections, including those for Indivior PLC - Ordinary Shares, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.